AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine Syrup 1 mg/mL Rescue Treatment
Description: Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol 108 mcg Rescue Treatment
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 108 mcg Rescue Treatment
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 44 mcg Rescue Treatment
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 44 mcg Rescue Treatment
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
Study NCT00550550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
Study NCT03322371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 2-lead limited electroencephalography recording
Description: The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
Study NCT02208284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
Study NCT02208284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB 30 mg tablet
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral TDF/FTC
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral TDF/FTC
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for oral CAB
Description: Placebo tablets
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for oral TDF/FTC
Description: Placebo tablets
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Study NCT03164564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for CAB LA
Description: Administered as one 3 mL intramuscular injection in the gluteal muscle
Study NCT01871493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)
Study NCT03036059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 μg/kg Ivermectin + 400 mg Albendazole
Description: 400ug/Kg, tablet, given orally once or twice a year.
Study NCT03036059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 μg/kg Ivermectin + 400 mg Albendazole
Description: 400ug/Kg, tablet, given orally once or twice a year.
Study NCT02390739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
Study NCT02390739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT02390739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
Study NCT02390739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thyroglobulin mTCR PBL
Description: On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
Study NCT05822921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person Psychoeducation (IP)
Description: Parents will attend two 60-minute (i.e. one day per week, for the next two weeks), in-person psychoeducation sessions on the MAC, in or near their hometown. During these sessions, a clinician will discuss a series of psychoeducation topics supplemented with PowerPoint slides. Across the two sessions, the following topics will be covered: (1) signs/symptoms and epidemiology of ASD, (2) risk factors associated with developing ASD (e.g., genetics, neurobiology, environment, social motivation), (3) navigating the IEP process, and (4) evidence-based best practices recommended for their child's profile of ASD symptoms and co-occurring conditions. This delivery method will allow parents to ask questions and receive immediate, live, and detailed answers from an expert clinician, to focus on specific examples relevant to their child, and to foster ASD knowledge and efficacy in helping their child.
Study NCT05822921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Psychoeducation (TH)
Description: Parents in this group will attend two 60-minute sessions, remotely via a live video chat platform, rather than in-person. Otherwise, it will follow the same format and PowerPoint materials as the IP Group. Sessions will still be facilitated by a clinician, thus maintaining the option to ask questions, discuss personalized examples, etc. For families without computer and internet access, the family will be assisted with to connecting to internet access at a private and convenient location (e.g., a church, library, or local community services agency). In the event that this is not possible, the family will be randomized to one of the other two groups.
Study NCT05822921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation as Usual (PAU)
Description: Parents in this group will receive basic paper psychoeducation resources, distributed at their feedback session. It will be up to each parent how frequently and diligently these resources are reviewed. This should be akin to what a family might have access to at their pediatric or primary care office. To be consistent across study groups, the materials produced for these parents will be comprehensive and will include the same span of content as the PowerPoint slides used in the other two groups, but without structured sessions facilitated by a clinician. Upon distribution of materials, parents will be provided with our contact information and encouraged to reach out if any questions occur. Parents in the paper informational materials group will have the option to complete two in-person or video conference psychoeducation sessions after the end of the study, if preferred (i.e., 6 months later).
Study NCT00987064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature controlled Laminar Airflow (Protexo)
Description: The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
Study NCT00987064 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TLA
Description: TLA treatment with disabled filtration function
Study NCT03846414 — intervention group
Intervention type: DRUG
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
Study NCT02640391 — intervention group
Intervention type: OTHER
Intervention: colonoscopy
Study NCT02601716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
Study NCT02601716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
Study NCT02601716 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CHMI (7G8)
Description: CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
Study NCT02601716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI (NF135.C10)
Description: CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
Study NCT02601716 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CHMI (NF135.C10)
Description: CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
Study NCT01199159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
Study NCT01199159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B 6
Description: 20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
Study NCT01623648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 Whey Breakfast
Description: The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
Study NCT01623648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 No Whey Breakfast
Description: The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
Study NCT01623648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arm 3 Low Protein Breakfast
Description: The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
Study NCT01222923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg orally disintegrating tablets
Study NCT01222923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg orally disintegrating tablets
Study NCT02871830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 15 mins physical activity per day within the school setting.
Study NCT03288896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
Study NCT03520465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh®-CICAT longitudinal measure 10x35 cm
Study NCT04890795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: 10mg/tablet;Oral administration, once daily.
Study NCT03311932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: Immediate release multiparticulate formulation (granules) of hydrocortisone
Study NCT03311932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef®
Description: Immediate release hydrocortisone tablets
Study NCT00508352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helical tomotherapy IMRT
Description: Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
Study NCT00002760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Description: 400 mg PO tid for as long as treatment is effective
Study NCT00002760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Description: hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
Study NCT00002760 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Withdrawal of antiandrogen therapy
Description: no drugs given
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50 mg b.i.d
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin is to be kept unchanged
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin is to be kept unchanged
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfonylurea (SU)
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Study NCT01871558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin
Study NCT01152294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD & Booklet called: Managing Menopause
Description: DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
Study NCT02684201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Stimulator Lead
Description: A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
Study NCT03713021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TraceIT Tissue Marker
Description: The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
Study NCT02408237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS Ambulatory
Description: Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
Study NCT02408237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS Ambulatory
Description: In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
Study NCT02408237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS Home use
Description: The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
Study NCT02408237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS Home use
Description: The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
Study NCT00374660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.
Study NCT00374660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
Study NCT02040558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-010
Study NCT00813137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox4 plus recombinant human endostatin (Endostar)
Description: Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16